Case Studies – Stem Cell Therapy for Parkinson’s Disease

Our experience of Stem Cell Therapy for Parkinson’s Disease in working with patients diagnosed with Parkinson’s disease spans more than 22 years. During this time, our medical specialists have developed experience in regenerative medicine and cell-based approaches for neurological disorders. Our clinic follows an individualized approach to patients with Parkinson’s disease, taking into account the stage of the disease, predominant symptoms, age, general health and associated medical conditions.

We operate as a full-cycle medical network with our own cryobank, laboratory facilities and clinical departments, allowing different stages of the treatment process to be coordinated within an integrated medical system. Our laboratory in Graz, Austria, is an important part of our scientific and laboratory infrastructure. We are also a member of the European Association of Biobanking and Scientific Research and cooperate with partner clinics abroad, including medical facilities in Ukraine and Bulgaria . Our team also conducts research and develops regenerative medicine protocols aimed at neurological and neurodegenerative conditions. Stem cell therapy is effective for Parkinson’s disease

Our Approach to Stem Cell Therapy for Parkinson’s Disease

Parkinson’s disease is a complex neurodegenerative disorder associated with the progressive loss of dopamine-producing neurons and a wide range of motor and non-motor symptoms. Modern regenerative medicine research is investigating whether cell-based therapies may support damaged neural systems, influence the tissue environment and, in some approaches, replace or support dopaminergic neurons.

Our treatment programs are individualized rather than based on one identical protocol for every patient. Depending on the patient's clinical condition and medical assessment, different cell-based approaches may be considered. These can include mesenchymal stem cells, IPSC, neural or neural-crest-related cellular components and cell-derived products such as exosomes, mitochondria, neurotrophins. The rationale for different cellular components is based on their biological characteristics, including paracrine signaling, immunomodulatory effects and potential neurotrophic activity.

Administration routes may also vary according to the individual treatment program. These may include intravenous, local, paravertebral or intrathecal administration. The objective is to develop an individualized regenerative medicine strategy while taking into consideration the patient's neurological symptoms and overall medical condition.

It is important to emphasize that stem cell therapy for Parkinson’s disease remains an evolving field of clinical research. Patient testimonials and individual case studies can describe meaningful changes experienced by particular patients, but they cannot establish that the treatment will produce the same outcome in every person.

Patient Case 1: 69-Year-Old Man from the Netherlands

Patient: W.H.
Age: 69
Country: Netherlands
Diagnosis: Akinetic-rigid, tremor-dominant Parkinson’s disease, Hoehn & Yahr stage II
Additional conditions: Stage III hypertension, diffuse cardiosclerosis, left bundle branch block without heart failure
Treatment dates: April 18–19, 2023 and June 4–5, 2025

This patient underwent stem cell treatment as part of his management for Parkinson’s disease. Following subsequent treatment, he reported a general improvement in his condition. His friends also noticed a visible improvement in his gait.

According to his follow-up communication, he was able to walk for approximately one hour every day and continued performing Parkinson’s-specific physical exercises. He described his condition as having reached a better level of balance.

Before and After – Patient W.H.

Before treatment	Follow-up experience
Parkinson’s disease with tremor and rigidity	Patient reported general improvement
Impaired gait and balance	Friends noticed improved walking
Stage II Parkinson’s disease	Continued regular daily walking
Neurological motor symptoms	Continued Parkinson’s exercises
Reduced functional confidence	Patient described improved balance

The patient's experience demonstrates the importance of assessing functional outcomes such as gait, balance and physical activity when following patients after regenerative treatment for Parkinson’s disease.

Patient Case 2: 63-Year-Old Woman from Jordan

Patient: J.S.H.
Age: 63
Country: Jordan
Diagnosis: Akinetic-rigid Parkinson’s disease with dominant tremor
Additional conditions: Circulatory encephalopathy, mild vestibular syndrome, signs associated with levodopa overdose and other chronic conditions
Treatment date: September 9–10, 2021

This case was reported by the patient's daughter following stem cell treatment. According to her communication, noticeable changes were observed during the weeks following treatment. After Stem Cell Therapy for Parkinson’s Disease, she reported that approximately two weeks after treatment her mother was feeling significantly better, and around 21 days after treatment some symptoms had decreased.

The family particularly noted changes in general condition and digestion. At the same time, the patient continued to experience episodes of falling when attempting to stand, demonstrating that the response was not complete and that significant neurological limitations remained.

Before and After – Patient J.S.H.

Before treatment	Follow-up experience
Akinetic-rigid Parkinson’s disease	Family reported overall improvement
Dominant tremor	Some symptoms were reported as reduced
Vestibular symptoms	General condition described as better
Multiple associated conditions	Digestive symptoms reportedly improved
Mobility and balance limitations	Falls didn't occurre

This case illustrates why patient outcomes should be evaluated comprehensively. Improvement in some symptoms does not necessarily mean complete recovery from Parkinson’s disease.

Patient Case 3: 72-Year-Old Woman from Kuwait

Patient: Female
Age: 72
Country: Kuwait
Diagnosis: Akinetic-rigid and tremor-dominant Parkinson’s disease, Hoehn & Yahr stage I
Additional conditions: Hypertension, heart failure with preserved systolic function, osteochondrosis, pain, previous spinal surgery and right lower-leg monoparesis
Treatment date: June 5–6, 2022

Four months after treatment, the patient's daughter provided a follow-up report. She described a reduction in the patient's usual bone pain and reported that night pain had disappeared, allowing her mother to sleep more comfortably.

The family also reported improvement in the condition of the affected lower limb and reduced stiffness. However, the patient had not yet regained independent walking and continued physical therapy. Stem Cells Therapy for Parkinson’s Disease: Case Study

Before and After – Patient 72

Before treatment	Four-month follow-up
Parkinson’s disease with rigidity and tremor	Family reported reduced stiffness
Significant musculoskeletal pain	Usual bone pain reportedly decreased
Night pain	Night pain reportedly absent
Mobility limitations	Walking remained limited
Lower-limb neurological impairment	Some improvement reported
Required rehabilitation	Continued physical therapy

This case demonstrates that regenerative treatment may be evaluated not only through classic Parkinson’s motor symptoms but also through mobility, pain, sleep and rehabilitation progress.

Patient Case 4: 69-Year-Old Woman from the USA

Patient: H.R.
Age: 69
Country: USA
Diagnosis: Akinetic-rigid and tremor-dominant Parkinson’s disease, Hoehn & Yahr stage II
Additional condition: Grade II–III left-sided scoliosis
Treatment date: November 18–19, 2020

Following treatment, the patient's family reported several positive changes. They described improved walking, reduced back pain and better bowel function. The patient was also reported to be more active and to smile more frequently.

The patient's experience demonstrates the importance of monitoring both motor and non-motor symptoms in Parkinson’s disease. Changes in mobility, pain, gastrointestinal function, sleep, mood and daily activity can all influence quality of life.

Before and After – Patient H.R.

Before treatment	Follow-up experience
Stage II Parkinson’s disease	Family reported general improvement
Walking difficulties	Walking reportedly improved
Back pain	Back pain decreased
Gastrointestinal difficulties	Bowel function improved
Reduced activity	Increased activity reported
Overall reduced well-being	Family described improved general condition

The reported changes represent the patient's individual experience and cannot by themselves establish the effectiveness of stem cell therapy for Parkinson’s disease.

Patient Case 5: 62-Year-Old Man from Russia

Patient: N.N.
Age: 62
Country: Russia
Diagnosis: Parkinson’s disease
Treatment: December 2020

Before treatment, the patient experienced “off” periods throughout the day, severe difficulty walking, significant balance problems, tremor in the right arm and leg, marked rigidity and incontinence.

After treatment, his wife described noticeable changes in mobility and balance. According to her report, the weakness in his leg had almost disappeared, he was able to turn more freely and could walk sideways and step over objects more easily. She also described an improvement in his ability to look around while walking without losing balance.

Before and After – Patient N.N.

Before treatment	Follow-up experience
Frequent “off” periods	Patient reported improved mobility
Severe walking difficulty	Walking became easier according to family
Significant balance impairment	Balance was reportedly better
Right-sided tremor	Improvement was reported by the family
Severe rigidity	Greater freedom of movement was described
Difficulty turning and walking sideways	Turning and sideways walking reportedly improved
Leg weakness	Weakness was reported as substantially reduced

This case is particularly focused on functional mobility. Improvements in turning, balance and walking are important outcomes for patients with Parkinson’s disease because these symptoms can significantly affect independence and everyday activities.

What Can These Parkinson’s Disease Cases Tell Us?

Taken together, these individual case studies describe a broad range of patient-reported experiences after stem cell treatment for Parkinson’s disease. Reported changes included gait and balance, tremor, rigidity, mobility, pain, sleep, gastrointestinal function, physical activity and general quality of life.

At the same time, the cases demonstrate that responses can differ substantially. Some patients reported improvements in mobility or general well-being, while others continued to experience important neurological limitations or required ongoing rehabilitation. Parkinson’s disease is highly individual, and treatment outcomes may depend on disease stage, symptom profile, associated conditions and many other factors.

The growing field of regenerative neurology is investigating different cell-based strategies for Parkinson’s disease, including mesenchymal stem cells, neural progenitor or dopaminergic cell approaches and cell-derived biological products. Research is focused on mechanisms such as neurotrophic signaling, modulation of inflammatory pathways and, in some approaches, restoration of dopamine-producing neuronal populations.

Our experience with Parkinson’s disease patients for more than 22 years, combined with laboratory capabilities, cryobanking, clinical infrastructure and research activities, allows us to develop individualized approaches to regenerative medicine. However, patient testimonials and case studies should be viewed as descriptions of individual experiences rather than as proof of a guaranteed therapeutic effect.

For patients considering stem cell therapy for Parkinson’s disease, a detailed neurological evaluation is essential. Treatment planning should take into account the patient's diagnosis, disease stage, medications, neurological symptoms, comorbidities and rehabilitation needs. Long-term follow-up is also important for evaluating functional changes and the durability and safety of any cell-based treatment.